LEADER 04423nam 22005535 450 001 9910349444703321 005 20200701071335.0 010 $a3-030-00054-0 024 7 $a10.1007/978-3-030-00054-7 035 $a(CKB)4100000009191094 035 $a(DE-He213)978-3-030-00054-7 035 $a(MiAaPQ)EBC5894523 035 $a(PPN)257359303 035 $a(EXLCZ)994100000009191094 100 $a20190909d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aChagas Disease $eA Clinical Approach /$fedited by Jaime Marcelo Altcheh, Hector Freilij 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (XII, 356 p. 48 illus., 34 illus. in color.) 225 1 $aBirkhäuser Advances in Infectious Diseases,$x2504-3811 311 $a3-030-00053-2 327 $aOverview -- Chapter 1: Chagas disease: past, present and future -- The agent -- Chapter 2: Trypanosoma cruzi Journey from the Insect Vector to the Host Cell -- Chapter 3: A panoramic view of the immune response to Trypanosoma cruzi infection -- Epidemiology -- Chapter 4: Epidemiology of Chagas Disease -- Chapter 5: Chagas Disease in Europe -- Chapter 6: Chagas Disease in the United States (USA) -- Diagnosis -- Chapter 7: Diagnosis of Chagas disease -- Clinical aspects -- Chapter 8: Acute vector-borne Chagas disease -- Chapter 9: Congenital Chagas Disease -- Chapter 10: Chronic Trypanosoma cruzi Infection: Decision Making in the Midst of Uncertainty -- Chapter 11: Orally-Transmitted Chagas Disease: a Neglected Foodborne Infection -- Chapter 12: Gastrointestinal Chagas Disease -- Chapter 13: Chagas in immunosuppressed patients -- Treatment -- Chapter 14: CLINICAL PHARMACOLOGY OF DRUGS FOR THE TREATMENT OF CHAGAS DISEASE -- Chapter 15: In vivo Drug Testing for Experimental Trypanosoma cruzi Infection -- Chapter 16: Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities. 330 $aChagas disease is a potentially life threatening condition that was historically mainly endemic to Latin America. Over the last decade, however, the disease has spread to and is increasingly prevalent in other continents such as North America and Europe, with an estimated 7 million people infected worldwide. It is primarily transmitted by insect vectors that carry the parasite Trypanosoma cruzi, the disease agent. In areas where there is vector control and in non-endemic countries, it is mainly transmitted via congenital infection. Cardiac and gastrointestinal complications are common in untreated individuals.This book offers a comprehensive overview of Chagas disease, including its vectorial and congenital transmission, and molecular diagnosis, which is essential for screening, and developing and providing timely, effective anti-trypanosomal treatment. Written by experts working with infected patients on a daily basis, it discusses the pathogenesis of congenital, cardiac, gastrointestinal and oral Chagas disease, as well as its treatment and the pharmacological aspects of drug development in this area. The chapter, ?Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities? is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com. 410 0$aBirkhäuser Advances in Infectious Diseases,$x2504-3811 606 $aMolecular biology 606 $aParasitology 606 $aInfectious diseases 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aParasitology$3https://scigraph.springernature.com/ontologies/product-market-codes/B19002 606 $aInfectious Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33096 615 0$aMolecular biology. 615 0$aParasitology. 615 0$aInfectious diseases. 615 14$aMolecular Medicine. 615 24$aParasitology. 615 24$aInfectious Diseases. 676 $a611.01816 676 $a616.9363 702 $aAltcheh$b Jaime Marcelo$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFreilij$b Hector$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910349444703321 996 $aChagas Disease$91994004 997 $aUNINA